Aortic Valve Stenosis Screening Using Deep Learning on Noninvasive Arterial Pressure Waveforms.
BACKGROUND: Aortic stenosis (AS) presents a significant health burden. Early identification of significant AS, defined as at least moderate AS, may facilitate timely confirmatory testing, referral, and management. OBJECTIVES: This study sought to develop and externally validate a deep learning model applied to arterial pressure waveforms obtained from a noninvasive finger-cuff system to screen for significant AS, using transthoracic echocardiography as the reference standard. METHODS: This prospective international multicenter cohort study was conducted from December 2020 through July 2025. Participants underwent concurrent transthoracic echocardiography and noninvasive arterial pressure waveform acquisition. A 1-dimensional convolutional neural network was developed using the Cleveland Clinic development cohort and evaluated in a temporally distinct, multicenter validation cohort including sites in the United States, Spain, and the Netherlands. RESULTS: Significant AS was present in 307 of 3,634 (8.4%) patients in the development cohort and 241 of 1,336 (18.0%) in the validation cohort. In the validation cohort, the model demonstrated an area under the curve of 0.893 (95% CI: 0.876-0.910), with a sensitivity of 92.5% (223/241; 95% CI: 88.5%-95.2%), negative predictive value of 97.5% (706/724; 95% CI: 96.1%-98.4%), specificity of 64.5% (706/1,095; 95% CI: 61.6%-67.3%), and positive predictive value of 36.4% (223/612; 95% CI: 32.7%-40.3%). For severe AS, the area under the curve was 0.906 (95% CI: 0.890-0.922), with a sensitivity of 94.3% (183/194; 95% CI: 90.1%-96.8%), negative predictive value of 98.5% (706/717; 95% CI: 97.3%-99.1%), specificity of 64.5% (706/1,095; 95% CI: 61.6%-67.3%), and positive predictive value of 32% (183/572; 95% CI: 28.3%-35.9%). CONCLUSIONS: Deep learning applied to arterial pressure waveforms obtained from a finger-cuff system serves as a promising screening test for significant AS.
Authors
- Rhonda Miyasaka (ORCID: https://orcid.org/0000-0001-9961-0439)
- Eline Kho (ORCID: https://orcid.org/0000-0003-2001-4111)
- Jimmy Schenk (ORCID: https://orcid.org/0000-0003-0570-0017)
- Serge C. Harb (ORCID: https://orcid.org/0000-0002-7442-4928)
- Arghavan Arafati (ORCID: https://orcid.org/0000-0003-4172-1413)
- Richard A. Grimm (ORCID: https://orcid.org/0000-0003-3844-9850)
- Joseph T. Kassab (ORCID: https://orcid.org/0000-0001-6761-7636)
- Denise Petra Veelo (ORCID: https://orcid.org/0000-0001-6196-1671)
- Alexander P. J. Vlaar (ORCID: https://orcid.org/0000-0002-3453-7186)
- Patrick H. Collier (ORCID: https://orcid.org/0000-0003-3941-9653)
- Samir Ramesh Kapadia (ORCID: https://orcid.org/0000-0002-0026-3391)
- Brian P. Griffin (ORCID: https://orcid.org/0000-0001-6831-8611)
- Jay Ramchand (ORCID: https://orcid.org/0000-0001-8591-1986)
- Miguel Angel Gonzalez Reyes
Institutions
- Twitter (United States) (US)
- Cleveland Clinic (US)
- Cleveland Foundation (US)
- Hospital Universitario Reina Sofía (ES)
- Amsterdam University Medical Centers (NL)
- Edwards Lifesciences (United States) (US)
- University of Amsterdam (NL)
Publication Details
- Journal
- PubMed
- Published
- 2026-11-20
- DOI
- https://doi.org/10.1016/j.jacadv.2026.103475
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00